Table 2.

Outcomes

RT/temozolomide (N = 29)Vandetanib/RT/temozolomide (N = 69)P
OS, months, median (95% CI)15.9 months (11.0–22.5)16.6 months (14.9–20.1)0.8
PFS, months, median (95% CI)6.2 months (3.9–10.4)7.7 months (5.5–10.1)0.6
OS12 rate (95% CI)0.56 (0.40–0.80)0.68 (0.56–0.81)
PFS12 rate (95% CI)0.39 (0.20–0.57)0.25 (0.15–0.37)
PFS6 rate (95% CI)0.57 (0.37–0.73)0.58 (0.44–0.68)
Best radiographic response
 CR1/28 (3.6%)4/51 (7.8%)
 PR4/28 (14.3%)9/51 (17.6%)
 SD18/28 (64.3%)27/51 (52.9%)
 Pseudoprogression03/51 (5.9%)
 Progressive disease5/28 (17.9%)8/51 (1%)